Skip to content
Nikang Therapeutics
About Us
Science & Pipeline
News
Careers
Home
About us
Science & Pipeline
News
Careers
Erasca announced the dosing of a first patient in December 2020 in Erasca’s FLAGSHP-1 study, a Phase 1/1b clinical trial to evaluate ERAS-601, a SHP2 inhibitor discovered and developed by NiKang Therapeutics
See the press release on
Business Wire